Curriculum Vitae
Michael C. Tobes, MD, PhD, FACC
1783 Troup Hwy, Tyler, Texas 75701
Office (903)-595-2283 Fax (903)-597-2238

Practice

1997-Present	Cardiovascular Associates of East Texas, P.A., Athens, Texas

Education

General Education

1976 - 1979	University of Michigan - Ann Arbor, Michigan Post Doctoral Degree - Nuclear Medicine
1972 - 1976	University of Michigan - Ann Arbor, Michigan Doctor of Philosophy Degree, (Biological Chemistry)
1970 - 1972	University of Michigan - Ann Arbor, Michigan Master of Science Degree, (Biochemistry)
1966 - 1970	Michigan State University - East Lansing Michigan Bachelor of Science Degree (Biochemistry)

Medical Education

1993 - 1997	Fellowship – Cardiology Henry Ford Hospital, Division of Cardiovascular Medicine
1990 - 1993	Medical Residency - Internal Medicine Pennsylvania State University The Milton S. Hershey Medical Center
1988 - 1990	University of Miami School of Medicine - Miami, Florida Doctor of Philosophy to Doctor of Medicine Program

Board Certification

2004	Board Certification in Nuclear Cardiology

Licensure

1997	State of Texas
1994	State of Michigan

Hospital Appointments

UT Health East Texas (ETMC), Athens, Texas

Research

Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST segment elevation.

Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System.

Co-Investigator - REPLACE II - A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)

Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.

Co-Investigator – ER-TIMI 19 – A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI – the Early Retavase® (ER) – TIMI 19 Trial.

Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.

Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A phase III, randomized, open-label trial evaluating the efficacy and safety of ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavase™ / Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.

Co-Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.

Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter,double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-investigator - Niaspan Trial #MA-97-0101 Phase IV:an open-label-community-based clinical practice study of Niaspan in patients with hyperlipidemia.

Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non-Q wave myocardial infarction.

Co-investigator-PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.

Participant, National Registry of Myocardial Infarction 3, East Texas Medical Center – Athens, TX

Co-Principal Investigator - NIH Grant - HL-27555: "Heart Imaging Agents: A Structural Mechanistic Study".

Co-Principal Investigator – NIAMDD Grant 5-R01-AM-21477.

Co-Principal Investigator – DOE Grant DE-AC02-76EV02031: "Radiopharmaceuticals for Diagnosis and Treatment".

Co-Principal Investigator - NIAMDD Grant AM-21477: Radionuclide Adrenal Imaging in Hypertension".

Co-Investigator - NIH Grant 1-510-RR-02387: "Radionuclide Tomographic Camera and Dedicated Computer".

Co-Principal Investigator - Merrell Dow Pharmaceuticals, Inc., Merrell Research Center Grant: "A Phase I Clinical Study of Combination of DFMO and MGBG: Pharmacokinetic, Cellular, Biochemical, Pharmacological and Cytokinetic Effects".

Principal Investigator - NIH Grant - 1RO1-CA-32878: "Enzyme Inhibitors as Radiopharmaceutical Agents".

Co-Investigator - DOE Grant - DE-AC02-76EV02031: Radiopharmaceuticals for Diagnosis and Treatment."

Co-Principal Investigator - NIH Grant - 1-R01-HL-27555: "Heart Imaging Agents: A Structural-Mechanistic Study".

Co-Principal Investigator - NIH Grant - 1-RO1-CA-27244: "Mechanism based Inhibitors of Diamine Oxidase".